Clinical trials: Clopidogrel, completed
Inflammation, Thrombosis
Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients
This is a prospective, randomized, parallel design study to investigate that ticagrelor could attenuate inflammatory cell infiltration in thrombus aspirated from ST elevation myocardial infarction (STEMI) patients.
- Trial name
- NCT02639143
- Testing
- ticagrelor, Clopidogrel
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Drug Interaction of Clopidogrel
Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel
Clopidogrel is a platelets inhibitor that is widely used particularly during and after acute coronary events and coronary interventions. Several studies have shown that some patients are resistant to clopidogrel.
- Trial name
- NCT01269333
- Testing
- omeprazole, fluvoxamine
- Where
- Israel
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Head and Neck Cancer, Thromboembolism
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have…
- Trial name
- NCT00020189
- Testing
- acetylsalicylic acid, alvocidib, clopidogrel bisulfate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Coronary Artery Disease
Study of Policosanol to Improve Platelet Reactivity After Percutaneous Coronary Stent Implantation (PCI)
Thrombotic event is one of the most serious complications of coronary artery disease, which often result in myocardial infarction and even death.
- Trial name
- spirit (NCT01371058)
- Testing
- high maintenance clopidogrel, routine dual antiplatelet, policosanol plus dual antiplatelet
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Shenyang Northern Hospital
Antiplatelet Effect
Bleeding Time Study With AZD6482, Clopidogrel and ASA
The primary purpose of this study is to evaluate the effect of AZD6482 and clopidogrel on bleeding time when taken together with low-dose ASA.
- Trial name
- NCT00853450
- Testing
- AZD6482, Clopidogrel, ASA
- Where
- Sweden
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Aortic Valve Disease, Myocardial Infarction
Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI
The purpose of this study is to compare aspirin/acetylsalicylic acid+ clopidogrel with aspirin/acetylsalicylic acid alone as antithrombotic treatment following TAVI for the prevention of major ischemic events (MI, ischemic…
- Conditions
- Aortic Valve Disease, Myocardial Infarction, Stroke, Bleeding
- Trial name
- ARTE (NCT02640794)
- Testing
- Clopidogrel, Aspirin
- Where
- 4 sites in Canada, Chile and 1 more
- Volunteers
- 222 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Asymptomatic, Artery
Stenting Versus Best Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis
Background. Carotid artery stenting (CAS) recently has become an accepted method for treatment of patients with high-grade carotid artery stenosis, who are at an increased risk for surgical carotid endarterectomy (CEA).
- Trial name
- NCT00497094
- Testing
- carotid artery stenting
- Where
- Austria
- Volunteers
- 148 people
- Sponsor
- Vienna General Hospital
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
ARCANGELO (itAlian pRospective Study on CANGrELOr)
The Sponsor implemented a post-authorisation safety study (PASS), category 3, focused in Acute Coronary Syndrome, in order to collect information about the safety of cangrelor in the real clinical practice, evaluating the safety…
- Trial name
- ARCANGELO (NCT04471870)
- Where
- 30 sites in Italy
- Volunteers
- 1,005 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Healthy
Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor
The purposes of this study are to: Evaluate the tolerability of two cangrelor regimens. Compare the PD of cangrelor regimens with oral clopidogrel.
- Trial name
- NCT00102674
- Testing
- cangrelor
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Medicines Company
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947959
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Standard of care
- Where
- Germany
- Volunteers
- 665,533 people
- Sponsor
- Bayer
Platelet Aggregation Inhibitors
The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients
Background: Clopidogrel, an antiplatelet prodrug, is widely used for prevention of the recurrent cardiovascular events. CYP2C19 is one of the crucial enzymes for the activation of clopidogrel.
- Trial name
- NCT02711410
- Testing
- Clopidogrel
- Volunteers
- 518 people
- Sponsor
- National Cerebral and Cardiovascular Center, Japan
Heart Defects, Congenital
Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation
This study is the extension of the CLARINET study [NCT00396877 -EFC5314] in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt.
- Trial name
- CLARINET LT (NCT00833703)
- Testing
- Clopidogrel
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 49 people
- Sponsor
- Sanofi
Head Injury Trauma Blunt
Platelet Function Analysis in Head Trauma: ASA/Plavix
The investigators are assessing the platelet function analysis of those who sustained significant head trauma while on aspirin or plavix and to assess if any qualitative difference is obtained if platelets are administered.
- Trial name
- ASA/Plavix (NCT01534117)
- Testing
- Platelets, DDAVP
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Chang, Steve S., M.D.
Coronary Artery Disease
Tranexamic Acid in Clopidogrel Exposure to Decrease Hemorrhage and Transfusion
The use of platelet aggregation inhibitors, including aspirin and clopidogrel(CPDG), has become a standard management strategy for patients with acute coronary syndrome.
- Trial name
- TRACED (NCT01060163)
- Testing
- Tranexamic Acid, Saline
- Where
- 7 sites in China
- Volunteers
- 552 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Aortic Valve Disease, Myocardial Infarction
Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation
At present, a variety of antithrombotic regimens are prescribed in the early postprocedure period after transcatheter aortic valve implantation (TAVI).
- Conditions
- Aortic Valve Disease, Myocardial Infarction, Stroke, Bleeding
- Trial name
- POPular-TAVI (NCT02247128)
- Testing
- Aspirin + clopidogrel, Aspirin monotherapy, OAC + clopicogrel
- Where
- 17 sites in Belgium, Czechia and 2 more
- Volunteers
- 1,016 people
- Sponsor
- St. Antonius Hospital
Pharmacodynamic Interaction, Healthy Subjects
To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects
The primary objective of this study is to evaluate whether ASA, the combination of ASA and clopidogrel, and darexaban, which have different effects on blood coagulation, influence each other in their effects.
- Trial name
- NCT01409616
- Testing
- darexaban, darexaban (double dose), Acetyl Salicylic Acid
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Stable Angina
Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity
The purpose of this study is to evaluate if high-dose (80mg/day) atorvastatin might exert an adjunctive anti-platelet effect compared to high-dose clopidogrel (150mg/day) in stable patients with high on-treatment reactivity…
- Trial name
- ACHIDO (NCT01335048)
- Testing
- atorvastatin and clopidogrel, Clopidogrel
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Ospedale Misericordia e Dolce
Coronary Artery Disease
Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent
To compare the clinical outcomes of P2Y12 antagonist monotherapy with aspirin plus P2Y12 antagonist following 3-month of DAPT in patients undergoing PCI with bioabsorbable polymer Everolimus-eluting stents (Synergy®)
- Trial name
- NCT03447379
- Testing
- P2Y12 antagonist monotherapy, Aspirin plus P2Y12 antagonist
- Where
- South Korea
- Volunteers
- 1,452 people
- Sponsor
- Gangnam Severance Hospital
Coronary Artery Disease
Compare Ticagrelor vs Clopidogrel on the Reduction of Arterial Stiffness and Wave Reflectionsin Patients With CAD.
The purpose of this study is to investigate the potential acute and chronic effect of ticagrelor versus clopidogrel on arterial stiffness and other vascular risk markers of interest, the study will consist of two periods: a…
- Trial name
- NOVELTY (NCT02071212)
- Testing
- Ticagrelor
- Where
- Greece
- Volunteers
- 120 people
- Sponsor
- Hellenic Cardiovascular Research Society